Oblenio Bio is a biotechnology company that develops T-cell engager therapeutic candidates for autoimmune disease treatment.
Oblenio Bio has raised $62.0M in total funding. The most recent round was Series B. The last funding was announced in June 2026.
Oblenio Bio's investors include Pfizer Venture Investments, Deep Track Capital, Aditum Bio, GV.
Oblenio Bio is headquartered in Oakland, United States.
Oblenio Bio is a biotechnology company that develops T-cell engager therapeutic candidates for autoimmune disease treatment.
Oblenio Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Oblenio Bio — Funding & Investors." VCBacked, June 25, 2026, https://www.vcbacked.co/company/oblenio-bio. Accessed September 30, 2026.
VCBacked. (2026). Oblenio Bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/oblenio-bio
{{cite web |title=Oblenio Bio — Funding & Investors |url=https://www.vcbacked.co/company/oblenio-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated